Table 1.
Patient and cancer characteristics.
| Variable | Value |
|---|---|
| Patients and cancer characteristics at diagnostic | |
| Age, median [Q1–Q3] (years), (27 ‡) | 59 [53–66] |
| Histological subtypes, N (%), (27 ‡) | |
| High grade ovarian serous carcinoma | 25 (93%) |
| Others | 2 (7%) |
| FIGO stage at diagnosis, N (%), (27 ‡) | |
| I | 2 (8%) |
| III | 22 (81%) |
| IVB | 3 (11%) |
| BRCA mutations §, N (%), (27 ‡) | |
| BRCA1 | 19 (70%) |
| BRCA2 | 8 (30%) |
| Initial therapeutic management, N (%), (27 ‡) | |
| Induction/neoadjuvant platinum-based chemotherapy | 14 (52%) |
| Cytoreductive surgery | 25 (93%) |
| Complete resection achieved | 23 (85%) |
| Adjuvant platinum-based chemotherapy | 25 (93%) |
| Patient characteristics at olaparib initiation | |
| Age, median [Q1–Q3] (years), (27 ‡) | 63 [57–72] |
| ECOG-PS, N (%), (27 ‡) | |
| 0 | 5 (19%) |
| 1 | 16 (59%) |
| 2 | 6 (22%) |
| Body mass index (kg/m2), median [Q1–Q3], (25 ‡) | 23 [20–26] |
| Hemoglobin (g/dL), median [Q1–Q3], (26 ‡) | 11.8 [11.1–12.4] |
| White blood cells count (G/L), median [Q1–Q3], (25 ‡) | 5.1 [3.6–6.2] |
| Platelet count (G/L), median [Q1–Q3], (26 ‡) | 233 [187–288] |
| Serum albumin (g/L), median [Q1–Q3], (20 ‡) | 42 [39–44] |
| Estimated creatinine clearance (Cockcroft–Gault formula), median [Q1–Q3] (mL/min) (26 ‡) | 78 [54–97] |
| Cancer characteristics at olaparib initiation | |
| Olaparib introduction setting, N (%), (27 ‡) | |
| Maintenance after adjuvant chemotherapy | 7 (26%) |
| First relapse | 12 (44%) |
| Beyond first relapse | 8 (30%) |
| Number of metastatic sites, N (%), (27 ‡) | |
| Complete remission at olaparib initiation | 10 (37%) |
| 1 | 11 (40%) |
| 2 | 5 (19%) |
| 3 | 1 (4%) |
| Metastatic sites, N (%), (27 ‡) | |
| Peritoneal metastases | 15 (55%) |
| Node metastases | 4 (15%) |
| Visceral abdominal metastases | 3 (11%) |
| Extra abdominal metastases | 2 (7%) |
| Olaparib formulation and dosing, N (%), (27 ‡) | |
| Capsule 400 mg bid | 16 (59%) |
| Capsule 200 mg bid | 1 (4%) |
| Tablet 300 mg bid | 10 (37%) |
| Total | 27 (100%) |
‡ Number of patients with available data. FIGO: International Federation of Gynecology and Obstetrics (FIGO) classification (2014). § the somatic or germline status was not determined for all patients. ECOG-PS: Eastern Cooperative oncology Group Performance status.